Farletuzumab

Research use only, not for human use.

Farletuzumab (MORAb-003) is a humanized monoclonal antibody with a high affinity for folate receptor-α (FRα), acting as a potent inhibitor of FRα and impeding the growth of cells that overexpress this receptor, making it useful for cancer research.

Farletuzumab (MORAb-003) is a potent folate receptor-alpha (FRα) inhibitor. Farletuzumab is a humanized monoclonal antibody with high affinity for FRα. Farletuzumab possesses growth-inhibitory functions on cells overexpressing FRα. Farletuzumab can be used in research of cancer.

Farletuzumab (MORAb-003; 0-10 μg/mL; CHO-FR cells) inhibits FRα-dependent cell growth and increases folate EC50 in a dose-dependent manner.Farletuzumab (0.1-100 μg/mL; IGROV-1 cells; 1 h) mediates tumor cytotoxicity via complement dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC) in vitro.Farletuzumab (0-10 μg/mL; CHO-FR cells) inhibits phosphorylation of proteins by Lyn kinase, a member of the src family of kinases, thereby, blocking a FRa-mediated signaling pathway..Cell Cytotoxicity Assay Cell Line:IGROV-1 cells Concentration:0.1, 1, 10, and 100 μg/mL Incubation Time:1 hours Result:Had significant cytotoxicity at IGROV-1 cells.

——

——

Cell Cycle/DNA Damage

Antifolate

Antifolate

——

——

896723-44-7

——

>98% (HPLC)

——

——

——

(-20℃)

With Ice Pack

≥ 2 years